PDF(Pubmed)
Abstract：
UNASSIGNED: During the COVID-19 pandemic, antimicrobial and antifungal stewardship programs have lost their priority. Although all parenteral antifungals were used with the recommendations of infectious diseases specialists in the pre-pandemic period, most consultations were delayed during the pandemic because of the workload of infectious diseases specialists. In this period, antifungal treatments in hospitalized patients were managed by mostly primary physicians. Therefore, we aimed to detect the change in the consumption of antifungals during the pandemic.
UNASSIGNED: The data on the antifungal drug use by month and clinics, the number of beds, and the occupancy rate of the clinics were obtained from the hospital information registration system. We defined each drug according to the World Health Organization Anatomical Therapeutic Chemical (WHO ATC) coding system and determined the defined daily dose (DDD). The antifungal consumption (DDD/ 100 bed-days) in pre-pandemic and pandemic periods was compared.
UNASSIGNED: During the pandemic, the antifungal consumption increased two-fold (2019:7.43; 2020:18.03 DDD/100 bed-days). The highest antifungal consumption rate was in the hematology- oncology-hematopoietic stem cell transplantation (HSCT) clinics with 2.5-fold (2019:39.86; 2020:98.48 DDD/ 100 bed-days) increase. Liposomal amphotericin B consumption made up the majority of this with a four-fold increase in the hematology-oncology-HSCT clinics.
UNASSIGNED: We detected a dramatic increase in antifungal consumption in both ICUs and inpatient clinics during pandemic. A novel antifungal stewardship approach is urgently needed.
UNASSIGNED: The data on the antifungal drug use by month and clinics, the number of beds, and the occupancy rate of the clinics were obtained from the hospital information registration system. We defined each drug according to the World Health Organization Anatomical Therapeutic Chemical (WHO ATC) coding system and determined the defined daily dose (DDD). The antifungal consumption (DDD/ 100 bed-days) in pre-pandemic and pandemic periods was compared.
UNASSIGNED: During the pandemic, the antifungal consumption increased two-fold (2019:7.43; 2020:18.03 DDD/100 bed-days). The highest antifungal consumption rate was in the hematology- oncology-hematopoietic stem cell transplantation (HSCT) clinics with 2.5-fold (2019:39.86; 2020:98.48 DDD/ 100 bed-days) increase. Liposomal amphotericin B consumption made up the majority of this with a four-fold increase in the hematology-oncology-HSCT clinics.
UNASSIGNED: We detected a dramatic increase in antifungal consumption in both ICUs and inpatient clinics during pandemic. A novel antifungal stewardship approach is urgently needed.
摘要：
■在COVID-19大流行期间，抗菌和抗真菌管理计划已经失去了优先考虑。尽管在大流行前，所有肠胃外抗真菌药都与传染病专家的建议一起使用，大流行期间，由于传染病专家的工作量，大多数咨询都被推迟。在这个时期,住院患者的抗真菌治疗主要由主治医师管理.因此,我们的目标是检测大流行期间抗真菌药消费量的变化。
■按月份和诊所分列的抗真菌药物使用数据，床的数量,诊所的入住率是从医院信息登记系统获得的。我们根据世界卫生组织解剖治疗化学（WHOATC）编码系统定义了每种药物，并确定了定义的日剂量（DDD）。比较了大流行前和大流行时期的抗真菌药物消耗（DDD/100床日）。
■在大流行期间，抗真菌药物用量增加了两倍（2019年：7.43；2020年：18.03DDD/100床位）。抗真菌药物消耗率最高的是血液肿瘤造血干细胞移植（HSCT）诊所，增加2.5倍（2019：39.86；2020：98.48DDD/100床位天）。脂质体两性霉素B的消耗占其中的大部分，在血液学-肿瘤学-HSCT诊所中增加了四倍。
■我们发现大流行期间，ICU和住院诊所的抗真菌药物消耗量急剧增加。迫切需要一种新的抗真菌管理方法。
■按月份和诊所分列的抗真菌药物使用数据，床的数量,诊所的入住率是从医院信息登记系统获得的。我们根据世界卫生组织解剖治疗化学（WHOATC）编码系统定义了每种药物，并确定了定义的日剂量（DDD）。比较了大流行前和大流行时期的抗真菌药物消耗（DDD/100床日）。
■在大流行期间，抗真菌药物用量增加了两倍（2019年：7.43；2020年：18.03DDD/100床位）。抗真菌药物消耗率最高的是血液肿瘤造血干细胞移植（HSCT）诊所，增加2.5倍（2019：39.86；2020：98.48DDD/100床位天）。脂质体两性霉素B的消耗占其中的大部分，在血液学-肿瘤学-HSCT诊所中增加了四倍。
■我们发现大流行期间，ICU和住院诊所的抗真菌药物消耗量急剧增加。迫切需要一种新的抗真菌管理方法。
